Rapamycin /Everolimus

Rapamycin: one drug, many effects.


Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island.


Rapamycin and Alzheimer's disease: Time for a clinical trial?


Fasting and rapamycin: diabetes versus benevolent glucose intolerance.


Is Rapamycin a Dietary Restriction Mimetic?


Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.


Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis.


Rapamycin in ischemic stroke: Old drug, new tricks?


The Enigma of Rapamycin Dosage.


Rapamycin and ageing: when, for how long, and how much?


Rapamycin-resistant effector T-cell therapy.


mTOR: a pharmacologic target for autophagy regulation.


Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.


Adrenoceptor regulation of the mechanistic target of rapamycin in muscle and adipose tissue.


Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.


From rapalogs to anti-aging formula.


From causes of aging to death from COVID-19.


Is there a role for immunosuppression in antiphospholipid syndrome?


Rapamycin and rapalogs for tuberous sclerosis complex.


Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.


Longevity, aging and rapamycin.


Mechanistic target of rapamycin: integrating growth factor and nutrient signaling in the collecting duct.


Mammalian Target of Rapamycin (mTOR) as a Potential Therapeutic Target in Pathological Ocular Angiogenesis.


Tuberous sclerosis complex: review based on new diagnostic criteria.


Toward rapamycin analog (rapalog)-based precision cancer therapy.


On the Discovery of TOR As the Target of Rapamycin.


Pathogenesis and management of antiphospholipid syndrome.


Paradoxical aspects of rapamycin immunobiology in transplantation.


Rapamycin: friend, foe, or misunderstood?


Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome: implications for normal aging and age-dependent neurodegenerative disorders.


Rapalogs and mTOR inhibitors as anti-aging therapeutics.


Rapamycin in transplantation: a review of the evidence.


Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease.


Evidence for rapamycin toxicity in pancreatic beta-cells and a review of the underlying molecular mechanisms.


The mTOR signalling pathway in human cancer.


Towards a therapy for mitochondrial disease: an update.


Targeting mTOR with rapamycin: one dose does not fit all.


Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis.


Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.


Pulmonary manifestations in tuberous sclerosis complex.


mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.


Roles of mTOR Signaling in Tissue Regeneration.


Rapamycin in islet transplantation: friend or foe?


Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.


mTOR-targeted therapy of cancer with rapamycin derivatives.


Everolimus and sirolimus in transplantation-related but different.


The potential benefits of rapamycin on renal function, tolerance, fibrosis, and malignancy following transplantation.


Once again on rapamycin-induced insulin resistance and longevity: despite of or owing to.


Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.


Mammalian target of rapamycin inhibitor-associated stomatitis.


Target of rapamycin (TOR)-based therapy for cardiomyopathy: evidence from zebrafish and human studies.


Role of the mammalian target of rapamycin pathway in lentiviral vector transduction of hematopoietic stem cells.


Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.


Autophagy and cardiovascular aging: lesson learned from rapamycin.


Rapamycin plays a new role as differentiator of vascular smooth muscle phenotype. focus on "The mTOR/p70 S6K1 pathway regulates vascular smooth muscle differentiation".


Systemic therapy in metastatic renal cell carcinoma.


Molecular signatures of longevity: Insights from cross-species comparative studies.


Mammalian target of rapamycin signaling in cardiac physiology and disease.


Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.


The role of mechanistic target of rapamycin in maintenance of glomerular epithelial cells.


New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.


Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.


Oral and Topical Sirolimus for Vascular Anomalies: A Multicentre Study and Review.


Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases.


Dysregulation of Mammalian Target of Rapamycin Signaling in Mouse Models of Autism.


Frailty index as a biomarker of lifespan and healthspan: Focus on pharmacological interventions.


Protein translocation as a tool: The current rapamycin story.


Mammalian target of rapamycin (mTOR) pathways in neurological diseases.


Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae.


Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications.


Potential use of rapamycin in HIV infection.


Liver transplant immunosuppression during the covid-19 pandemic.


The target of rapamycin (TOR) proteins.


Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.


Rheb and mammalian target of rapamycin in mitochondrial homoeostasis.


Metabolic regulation, mitochondria and the life-prolonging effect of rapamycin: a mini-review.


Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies.


Energy restriction in renal protection.


mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.


Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.


The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors.


Conversion of calcineurin inhibitors with mammalian target of rapamycin inhibitors after kidney transplant.


Mammalian target of rapamycin: a central node of complex signaling cascades.


Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review.


The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses.


Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants.


Temsirolimus, an inhibitor of mammalian target of rapamycin.


Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.


Epstein-Barr virus, rapamycin, and host immune responses.


Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.


Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.


Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.


Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.


Rapamycin for chemoprevention of upper aerodigestive tract cancers.


Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.


Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.


Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma.


Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma.




Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling.


The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.


Importance of EEG in validating the chronic effects of drugs: suggestions from animal models of epilepsy treated with rapamycin.


Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.


Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent?


Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.


The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.




Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.


mTOR signaling in the differentiation and function of regulatory and effector T cells.


Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?


Next Generation Strategies for Geroprotection via mTORC1 Inhibition.


Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.


New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.


Leucine-enriched nutrients and the regulation of mammalian target of rapamycin signalling and human skeletal muscle protein synthesis.


Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.


Immunotherapy for metastatic renal cell carcinoma.


Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.


Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.


Targeting the mTOR pathway in breast cancer.


Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.


Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.


Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care.


The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.


Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry.


Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.


Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma.


The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.


Magmaris™ resorbable magnesium scaffold: state-of-art review.


Drugs that target aging: how do we discover them?

The Aging Heart.


Crohn's Disease: Potential Drugs for Modulation of Autophagy.


Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC).


Pharmacologic agents targeting autophagy.


What controls TOR?


Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.


Medical therapy for polycystic liver disease.


Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.


Architecture and activation of phosphatidylinositol 3-kinase related kinases.


Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.


Targeted therapy in lymphoma.


Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.


Conversion to sirolimus.


Determining sensitivity to rapamycin and its analogues in breast cancer patients.


Nutrition, metabolism, and targeting aging in nonhuman primates.


Koschei the immortal and anti-aging drugs.


The two faces of miR-29.


Updates of mTOR inhibitors.


Elucidation of the mTOR Pathway and Therapeutic Applications in Dermatology.


The role of mTOR in memory CD8 T-cell differentiation.


Preanalytical considerations in therapeutic drug monitoring of immunosuppressants with dried blood spots.


Role of mTOR Inhibitors in Kidney Disease.


TOR and paradigm change: cell growth is controlled.


Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.


Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.


Tuberous sclerosis complex: a brave new world?


mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression.


 Fetal Primary Cardiac Tumors During Perinatal Period.


Energetic interventions for healthspan and resiliency with aging.


Geroprotectors as a therapeutic strategy for COPD - where are we now?


Targeted Therapy for Metastatic Renal Cell Carcinoma.


Endovascular treatment of vasculogenic erectile dysfunction.


Age-Related Neurodegeneration Prevention Through mTOR Inhibition: Potential Mechanisms and Remaining Questions.


The therapeutic potential of mTOR inhibitors in breast cancer.


Targeting autophagy to sensitive glioma to temozolomide treatment.


mTORC1- and mTORC2-interacting proteins keep their multifunctional partners focused.


Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma.


mTOR inhibitors: an overview.


Searching for targets for the systemic therapy of mesothelioma.


Sirolimus--it doesn't deserve its bad Rap(a).


Emerging functions of autophagy in kidney transplantation.

Saphenous vein graft disease.


Novel agents in gastroenteropancreatic neuroendocrine tumors.


Tolerance in liver transplantation: Biomarkers and clinical relevance.


Pharmacological Modulators of Endoplasmic Reticulum Stress in Metabolic Diseases.


Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.


Immunosuppressive minimization with mTOR inhibitors and belatacept.


Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.


Calcineurin inhibitor-free protocols: risks and benefits.


Will kinase inhibitors make it as glioblastoma drugs?


Posttransplant anemia: the role of sirolimus.


Targeting the PI3K-AKT-mTOR signaling network in cancer.


Modeling new therapies for infantile spasms.


Sirolimus: a current perspective.


Successful management of anemia with sirolimus in blue rubber bleb nevus syndrome: case report and update.


Clinical development of mTOR inhibitors in breast cancer.


Impact of genetic alterations on mTOR-targeted cancer therapy.


Cellular and molecular targeting for nanotherapeutics in transplantation tolerance.


Fully bioresorbable drug-eluting coronary scaffolds: A review.


Current options for the treatment of facial angiofibromas.


Rapalogs in cancer prevention: anti-aging or anticancer?


 mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?


mTOR-inhibiting pharmacotherapy for the treatment of non-infectious uveitis: a systematic review protocol.


Dysregulation of mTOR activity through LKB1 inactivation.


Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.


Targeting the intracellular signaling "STOP" and "GO" pathways for the treatment of alcohol use disorders.


Caloric restriction and chronic inflammatory diseases.


Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.


Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.


Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.


Systemic therapy for advanced pancreatic neuroendocrine tumors.